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Abstract
Background

An aging population means an inevitable increase in cancer diagnoses, and
thus, a novel solution is needed to address this looming problem. Within the
field of breast cancer, thermal ablation has emerged as a promising
alternative to surgical excision. As a minimally invasive treatment, it
significantly reduces the morbidity and mortality for geriatric patients, as
well as healthcare costs overall.

Purpose

The purpose of this analysis is to understand the utility of thermal ablation
for the treatment of invasive ductal carcinoma. Specifically in the context of
elderly patients, it is determined if this treatment modality is superior to
traditional breast conserving surgery.

Methods

A comprehensive literature review was conducted using Augsburg
University Lindell Library database, Google Scholar, PubMed,
ScienceDirect and Wiley Online Library using the search terms breast
cancer, percutaneous thermal ablation, cryoablation, radiofrequency ablation,
high-intensity focused ultrasound, microwave ablation, laser ablation,
histopathology, margin evaluation and geriatric. Inclusion criteria was
studies published after 2015 using thermal ablation as primary treatment of
breast cancer. Exclusion criteria were studies published prior to 2015 and
patients were provided neoadjuvant therapy.

Results

Cryoablation and radiofrequency ablation are the most effective in achieving
complete tumor ablation and preventing local recurrence. Laser ablation,
microwave ablation and high-intensity frequency ultrasound are in their
infancy of development and warrant further research.

Conclusions

Thermal ablation is a reasonable alternative to surgical excision in the elderly
and those unsuitable for surgery. Application of these techniques will be
crucial to meet the healthcare demand of an aging population in the near
future.

Key words

Thermal ablation, cryoablation, RFA, LA, MWA, HIFU, breast cancer,
IDCA, elderly
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Thermal Ablation as an Alternative to Standard Breast Conserving Surgery
in the Treatment of Invasive Ductal Carcinoma of the Elderly

Introduction
The lifetime risk of developing breast cancer is 1 in 8 women.1 The pervasiveness of this
disease makes it the leading cause of cancer related death in females, and the second most
frequently diagnosed malignancy around the world.2 In the United States alone, it is estimated
290,000 new cases of breast cancer will be diagnosed in 2022.1 The global rise in cases coincides
with the expansion of screening programs and imaging technology. More importantly, however,
these advances increase the likelihood of identifying tumors earlier in their development, thereby
providing patients with a highly favorable prognosis. The magnitude of this trend is illustrated by
a 2021 meta-analysis: it reports nearly half of all diagnosed breast cancers measure less than 2
cm upon diagnosis, which equates to an excellent 5-year-survival-rate of 98%.3
Surgical excision endures as the gold standard of primary intervention for breast cancer;
however, over the past four decades, trends have opted towards utilizing less invasive
techniques. From the radical and nipple sparing mastectomy, the lumpectomy evolved as the
latest customary approach to breast conserving surgery.2 Reducing the volume of removed tissue
lessens patient morbidity and preserves aesthetics, without jeopardizing the effectiveness of
treatment.3 Yet, the unyielding demand for modesty is pushing the field towards avoiding the
operating room altogether. A promising frontier is the use of thermal energy to destroy tumor
cells. Application of either hypo- or hyperthermic temperatures can be performed through the
skin, presumably without the need for general anesthesia. The most studied percutaneous thermal
ablation techniques include cryoablation, radiofrequency ablation (RFA), laser ablation (LA),
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microwave ablation (MWA) and high-intensity frequency ultrasound (HIFU).4 These novel
methods very precisely obliterate a designated tumor volume, without compromising healthy
surrounding tissue. As an alternative to surgical resection, thermal ablation can lower costs for
both patients and facilities; in-office procedures lessen staff requirements, resource consumption
and hospitalizations, while maintaining positive morbidity and cosmesis outcomes. 2
This innovation is especially impactful in the geriatric population, where the risks of
surgery are complicated by frailties of extreme age and comorbid conditions.4 Breast cancer is
most commonly diagnosed in the sixth and seventh decade. In a study of 120,000 women,
recommendations against surgery were primarily due to patients being of senior age.5 As the
brain grows older, it is less resilient to the neurotoxins induced by general anesthesia;
accumulation leads to cerebral inflammation and postoperative cognitive dysfunction.6
Additionally, elderly patients are at greater risk of acquiring hospital borne illnesses following
surgery, including pneumonia, urinary infections and pressure injuries.7 The above elements
frequently lead physicians to offer systemic-only treatment for these patients. However, the value
of local excision cannot be overlooked; its omission from the treatment algorithm is proven to
lead to poorer outcomes, reinforcing the necessity for minimally invasive interventions. 5
Advancements in breast cancer genomics and accumulation of experience with thermal
ablation have identified a favorable subset of patients to undergo this treatment modality; those
most likely to benefit are diagnosed with early-stage invasive ductal carcinoma (IDCA)
measuring less than 2 cm in diameter, and whose tumor biology is hormone receptor positive and
HER2 negative.8 Cancer cells with one or both estrogen (ER) or progesterone (PR) receptors are
characterized as “hormone-positive”; human epidermal growth factor receptor 2 (HER2) is a
protein that helps cancer cells grow quickly: breast tumors with higher-than-normal levels of
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HER2 are characterized as “HER2 positive”.3 Furthermore, thermal ablation is most appropriate
in addressing a single foci of tumor due to the highly localized nature of treatment probes.
Women with multifocal cancer, meaning the breast is inflicted with two or more distinct tumors,
require more extensive local treatment. Similarly, tumors classified as having an extensive
intraductal component (EIC) are also excluded. EIC is a term describing a unique form of cancer
which spreads diffusely throughout the breast; this is considered a significant risk factor for local
recurrence.9 All studies reviewed here utilize a benchmark of excluding tumors with EIC greater
than 25%. In the instance of multifocality or EIC, a mastectomy is most appropriate. Regardless
of intervention, adjuvant therapy is standard of care; this includes chemotherapy, radiation,
hormone and endocrine therapy.8 The course and combination of ancillary treatment is a shared
patient-provider decision, personalized to the patient’s age, specific tumor biology, the extent of
spread and other intricate factors.
A limitation of thermal ablation to this point is determining if complete tumor eradication
is achieved. Margin status is one of the most important factors influencing long term outcomes,
regardless of malignancy type.10 During a lumpectomy, sections of the surgical bed and tissue
surrounding the excisional site are sent to pathology for intraoperative evaluation, where the
presence of residual tumor may or may not be identified11 In the case of a positive margin, more
tissue will be excised by the surgeon until a negative result is achieved. Following surgery,
standard pathological evaluation ensues. This process involves formalin fixation and embedding
any removed tissue in paraffin wax, from which slides are prepared, and stained with standard
hematoxylin and eosin (H&E). The H&E dye highlights cellular structures allowing the
pathologist to identify the presence of residual tumor.12 This confirmatory practice is not yet
established in the case of thermal ablation. First, removing margins of tissue requires general
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anesthesia, which defeats the purpose of a minimally invasive in-office procedure.10 Second,
when margins are obtained, it is debated how to determine if cell death has occurred following
treatment; each ablative modality uniquely impacts the microcellular environment with the added
complexity of having a time-dependent effect.12 Third, imaging is unreliable in identifying
residual cancer following ablation, as well as detecting recurrence on follow-up scans.3
As detailed above, significant obstacles withstand the entry of thermal ablation into
routine clinical practice. However, for elderly patients who are poor surgical candidates or whose
preference is for minimal invasion, further understanding of its application is warranted. Owing
to the infancy of this treatment modality, not one standardized evaluation protocol exists.
Therefore, any effort to construct a meaningful conclusion in regards to thermal ablation’s
efficacy requires drawing from an eclectic pool of evidence. In the following literature review,
efficacy is assessed through several different means: margin involvement, biopsy, imaging, rate
of tumor recurrence and overall patient survival. The aim of the present analysis is to examine if
thermal ablation possesses a superior efficacy to that of conventional surgical intervention in the
treatment of IDCA. These results will be further explored in the setting of geriatrics as either
having legitimate application or if current treatment standards should be maintained.

Methods
A comprehensive literature review was conducted using the Augsburg University Lindell
Library database, Google Scholar, PubMed, ScienceDirect and Wiley Online Library. Key
search terms or phrases included breast cancer, percutaneous thermal ablation, cryoablation,
radiofrequency ablation, high-intensity focused ultrasound, microwave ablation, laser ablation,
histopathology, margin evaluation and geriatric. Primary research and controlled trials were
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utilized for analysis, and reviews as supportive evidence; animal studies were not considered.
The major study inclusion criteria were as follows: studies published in or after 2015 using
thermal ablation as principal intervention of primary breast cancer. A secondary inclusion
criterion was a focus on patients diagnosed with IDCA; it was not grounds for exclusion if
studies also included a minor patient pool with ductal carcinoma in situ (DCIS). While few
studies included patients with metastasis, the majority focused on patients with a singular breast
tumor without evidence of spread. A tertiary inclusion criterion was demonstration of
conditional post-procedural follow-up, such as surgical margin evaluation, imaging (ultrasound,
mammography, MRI, CT, PET scan) or needle core biopsy in addition to physical examination.
The major study exclusion criteria ruled out studies published in or before 2014, providing
patients neoadjuvant therapy, using thermal ablation to treat secondary metastatic lesions in the
breast or a primary focus on patients with metastatic breast cancer.

Review of Literature
To reiterate, the following are the most prominent thermal ablation procedures for the
treatment of IDCA: cryoablation, radiofrequency ablation (RFA), laser ablation (LA),
microwave ablation (MWA) and high-intensity forced ultrasound (HIFU). Cryoablation and
RFA have the longest studied histories, and hence, possess the most evidence of their efficacy;
therefore, each will be the focus of an independent section. More recently, successful
applications of LA, MWA and HIFU have been reported. Due to the smaller body of evidence,
these techniques will be the focus of a combined third section.
Furthermore, a commonality amongst all thermal ablation procedures is the use of image
guidance for placing and monitoring probe position. By far, ultrasound endures as the top choice
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of providers, though computed tomography scan (CT) and magnetic resonance imaging (MRI)
have also demonstrated utility. Image guidance allows providers to see their ablation tool in
relation to the tumor throughout the procedure. Additionally, thermal-induced damage of tissue
can be visualized in real-time, ensuring complete ablation is grossly achieved10
Below, a technical discussion of the ablation modality will be presented, followed by a
discussion of the current literature.

Part I: Cryoablation
As its name implies, cryoablation utilizes extreme cold to obliterate a tumor volume. This
modality has been successfully used for decades to treat various diseases in multiple organ
systems; most notably these include the lungs, liver, kidneys and prostate.4 Its initial application
in breast tissue was to treat fibroadenomas, until the late 1980s when its use expanded to cancer. 4
Cryoablation is an office-based procedure performed with local anesthetic, allowing patients to
stay awake. The cryoablation probe is inserted through a small incision made in the skin. Over
the course of 30-minutes, liquid nitrogen or argon gas is pumped into the cryoprobe. The site is
frozen (target temperature < -40℃), allowed to thaw, and then is frozen again.13 The goal is to
encase the tumor in ice, plus a circumferential margin of several millimeters; this process is
visualized on imaging and indicates the procedure was grossly successful.13 The most optimal
results are achieved when multiple probes are activated simultaneously with synergistic effects. 14
This series of freeze-thaw-freeze cycles leads to osmotic dehydration of tumor cells,
resulting in necrosis and apoptosis. These processes trigger the immune system to continue
mounting an attack on malignant cells in the weeks following cryoablation.8,13,15 A “stone-like”
consistency is palpable for 3-12 months along the zone of ablation, which resolves without
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changing the breast’s appearance.14 A notable strength of this modality is that post-operatively,
the hypothermic temperatures act as an intrinsic analgesic.16 Patients report minimal to no
discomfort in the days to weeks following treatment, and complications are rarely reported.

Studies
The Z1072 trial powered by the American College of Surgeons Oncology Group
(ACSOG) investigated the efficacy of cryoablation as primary treatment for IDCA. 9 Between
2009 and 2013, 86-patients underwent cryoablation followed by margin excision within a period
of 28 days; this method is termed the “treat-and-resect” protocol. ACSOG sought to determine
the rate of complete tumor ablation, defined as an absence of residual disease on pathological
examination. Margins were analyzed by an institutional pathologist, and then sent for central
review. The inclusion criteria for this study reflects the ideal candidate for thermal ablation:
patients with unifocal IDCA < 2cm in diameter and < 25% EIC. One patient had a singular
tumor in bilateral breasts, increasing the number of tumors assessed to 87. The mean patient age
and tumor size was 62 years and 1.2 cm, respectively.9
Z1072 demonstrates the effectiveness of cryoablation, while also highlighting a
significant gap in its advancement. In 84-cases, over 19 independent institutions, providers
successfully operated the device – speaking to its clinical adaptability; gross misplacement of the
cryoprobe was only seen in 2-cases9. Following double pathological evaluation, 66 of 87 (75.9%)
tumors were completely ablated, while 4 were partially ablated. Authors suggest in the latter, that
tumor size may have been initially underestimated on imaging or had poor demarcation, leading
to incomplete ablation. In 15-patients, post-ablation MRI revealed successful ablation of the
primary tumor; however, it also identified new tumor foci >2cm outside of this zone. ACSOG
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states these cases should not be considered an ablation failure. Notably, excluding this group
from study increases the complete tumor ablation rate from 75.9% to 92% (80 of 87 target
lesions). Astonishingly, authors report residual foci are commonly found outside the primary
tumor site in patients treated with breast conserving therapy.9 Therefore, while cryoablation is
effective at producing an adequate killing zone, it is highly dependent on pre-procedural MRI
quality and radiologist interpretation; these elements are crucial for adequate patient selection,
which greatly impacts the overall efficacy of cryoablation.
An earlier study in 2015 by Poplack et al. used the same treat-and-resect protocol but on
a smaller scale.16 Twenty patients with tumors < 2cm in diameter underwent cryoablation
followed by surgical excision 4-6 weeks later. All tissue was evaluated by an institutional
pathologist; 10 patients’ tissue was sent for a secondary blinded analysis. Histology revealed
pathologically distinct zones: central ischemia and coagulative necrosis, surrounded by a region
of inflammatory changes and fat necrosis, then finally a peripheral ring of normal fat and
fibroglandular tissue. Within this latter zone, residual cancer was found in 3-patients. As in
Z1072, this implies the cryoprobe was likely misplaced, rather than ablation failure in the central
zone. These patients also shared an initial diagnosis of DCIS, versus IDCA, which literature
proves is harder to eradicate with thermal ablation in general due to the non-discrete margination
of these tumors.3 Results of the Poplack et reinforce the effectiveness of cryoablation, especially
given blinded review in 50% of patients by a centralized, independent pathologist.16
The following studies differ from Z1072 and Poplack et al. in that margins are not
utilized to verify efficacy. Therefore, proving the non-inferiority of cryoablation to surgical
intervention is challenging. Habrawi et al. is a significantly smaller powered prospective study.
12-women recruited with hormonal positive, HER2 negative IDCA measuring < 1.5 cm in

Ducharme 12
diameter were treated with cryoablation without subsequent excision; follow-up was scheduled
every 6 months with the intent to follow patients for 2 years.4 At 6 months, 11 of 12 patients
presented for post-procedural mammography, ultrasound and MRI with no identifiable cancer.
Confirmatory needle biopsy in 4 patients demonstrated fat necrosis in place of viable tumor cells,
indicating successful ablation; these results were corroborated on ultrasound and MRI. At 1 year,
imaging was negative for 8-patients, and at 2 years, 4 patients were negative for recurrence.
Though on a very small scale, Habrawi et al. demonstrated cryoablation was effective in
avoiding recurrence of IDCA in at least 4 patients.4 Yet, the evidence presented here is weakened
by lackadaisical, vague follow-up criteria set by the authors. At 1-year, 30% of patients failed to
return to the clinic and by 2 years, 66% were lost to follow-up.4 Lastly, it is not stated if the same
patients followed up serially, or if each interval consisted of different patients, weaking the
longitudinal value of this study.
The ICE3 trial is an industry sponsored, prospective study that also waived excision
following cryoablation.8 This 2021 paper reflects the 3-year interim analysis of the study’s
anticipated 5-year span (tentative completion date of 2023). 194-patients were recruited from
several institutions to determine the efficacy of a newly developed cryoprobe device. Authors
acknowledge that omitting definitive surgical management likely biased physicians towards
choosing low-risk elderly participants. The mean patient age and tumor size was 75 years and 0.8
cm, respectively.8 Additional selection bias is seen in this latter element. As tumor size
decreases, treatment effectiveness increases; by narrowing in on the population most likely to see
benefit, authors strategically build evidence for their device.
Despite significant bias, results of ICE3 underscore the effectiveness of cryoablation in
avoiding ipsilateral breast tumor recurrence (IBTR). At the 3-year interim, 98% (191/194) of
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patients were negative for IBTR; the mean time to recurrence in the remaining 2% was 43
months.8 All patients were treated as outpatients and 76% report returning to full daily activities
within 2 days of treatment. In agreement with Habrawi et al., ICE3 authors discuss reabsorption
of fat necrosis over time on mammography, indicating successful cryoablation. Since 2019, 10patients have died due to advanced age and preexisting comorbidities, not related to the device. 8
Though, this dropout rate is expected with an aging participant pool. At the completion of its 5year study period in 2024, results of ICE3 will further validate the reliability of cryoablation
without subsequent excision in select patients.
Cazatto et al. is an earlier study published in 2015, and like ICE3, documents
cryoablation without subsequent excision in elderly, non-operable patients; median age is 85
years with a median tumor size of 1.4 cm.14 Authors delineate a “dual-freezing” and a more
aggressive “triple-freezing” protocol, which 10 and 13 patients received respectively. Over the 2year follow-up period, 1 patient died due to myocardial infarction; of the remaining 22 patients,
the local tumor control was 76.9% at 1 year and 9% at 24 months. Similar to Habrawi et al,
adherence to follow-up protocol was poor: only 5-patients returned for the 2-year follow-up.4,14
Therefore, the results of this study require careful interpretation. Yet, on the whole, only 5
patients experienced recurrence, and were successfully re-treated with either another round of
cryoablation or adjuvant therapy.14 These results are in agreement with ICE3,, but on a much
smaller scale (n=194 vs n=23, respectively).4,8,14 Patients grossly unsuitable for surgery are a
minority, and therefore the small study size is a limitation of this trial. Taken together, however,
these studies prove cryoablation alone is well tolerated by the geriatric population, with
relatively high efficacy in controlling local recurrence.
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The following study focuses on the predictive value of imaging to detect residual and
recurrent cancer following cryoablation, which is essential for its clinical adoption. MRI detects
tumor vascularity and is a non-invasive method to assess ablation and adjuvant therapy
responses.15 Machida et al. recruited 2 radiologists (observer 1, observer 2) with 16-years of
experience to retrospectively look at 54 cases of patients with breast cancer who underwent
cryoablation; charts from 2006-2014 were subject to review.15 Patients were a mean age of 56
years and diagnosed primarily with hormonal positive, HER2 negative IDCA that measured less
than 1 cm (median size 0.89 cm). Preemptively, radiologists reviewed non-participant scans to
agree upon what they considered abnormal enhancement. From this point, radiologists were
blinded to clinical outcomes and asked to assess MRIs for patients post-cryoablation. Statistical
analysis scored interobserver agreement using k values: slight (<0.20), fair (0.21-0.40), moderate
(0.41-0.60), substantial (0.61-0.80), or almost perfect (0.8-11.0). Post-ablation MRIs were
performed an average of 42 days after treatment.15 However, the mean time between postablation MRI and the start of radiation varied widely, which likely impacted the ablation zone’s
appearance of imaging.
Both observers agreed, between the first and second post-ablation MRI, the treatment
zone shrank (p <0.001).15 Contrarily, interobserver agreement on enhancement shape and degree
of suspicion for residual disease or recurrence was only fair to moderate between MRIs. This k
value is considerably low and raises concerns if the results presented here are generalizable. It
remains controversial what is considered suspicious enhancement within a treated area; this not
only varies between observer 1 and 2, but across the field as well. The predictive value of MRI is
a secondary outcome in Simmons et al. and Poplack et al.9,16 In the latter, the accuracy for
predicting treatment success was limited. Three of 18 participants showed residual cancer that
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MRI failed to detect, yielding a sensitivity of 0% (0/3).16 Simmons et al. showed low specificity
as well: 20% of cases predicted to be negative on MRI were deemed positive on histological
examination.9 In each of these studies, as well as Machida et al., the negative predictive value of
imaging proved to be less than reliable, underscoring its inadequacy to detect residual cancer.

Cryoablation has a longstanding history in the treatment of cancer; however, its reliability
to specifically detect breast cancer recurrence is questionable. In the van de Voort et al. 2021
meta-analysis, 37 thermal ablation trials were examined from the last twenty years.3 Of the 8
cryoablation studies included, the primary reasons given for incomplete ablation was multifocality detected on histologic evaluation and tumor size underestimation on pre-treatment
imaging. Each of these inconsistencies are highlighted by the Z1072 trial above. 3 The
development and implementation of more sensitive imaging will hurdle cryoablation into the
conversation of supplanting lumpectomy as standard of care. The combined analgesic effect of
cryoablation, with its moderate to high ablation efficacy, sustains this modality as a hopeful
option for elderly, non-surgical candidates.

Part II: RFA
RFA utilizes hyperthermic temperatures to obliterate tumor volume and is considered by
many in the field as the most promising of all ablative techniques. Already, it is a mainstay in the
treatment of hepatocellular and renal cell carcinoma, and commonly used in coronary catheter
ablation for atrial fibrillation.17 RFA was first used to treat breast cancer in the early 2000s. Yet,
general anesthesia continues to be required to withstand its high temperatures – defeating the
purpose of being a minimally invasive procedure.
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Under ultrasound-guidance, an electrode is advanced through a small skin incision into
the center of the tumor; echogenicity resulting from microbubble formation confirms proper
placement of the probe.12 Over the course of 45-minutes, an alternating electric current generates
ionic agitation, resulting in localized frictional tissue heating.18 When the site exceeds > 70℃,
protein denaturation occurs, followed by an ellipsoid region of necrosis. At this heat index, the
balance of temperature, therapeutic gain and adverse effects is a delicate practice: below the
threshold, tumor will not be adequately ablated, but excessive heat can lead to internal charring
and skin burns. Charring should be especially avoided as it acts as a very effective insulator,
disrupting homogenous heat distribution.19 A system of chilled water circulates beside the
electrode to minimize these issues.12 Once the tumor and an added margin of safety appear
completely hyperechoic on ultrasound, the procedure is considered grossly successful. Lastly,
“track ablation mode” is performed, where the pathway through which the electrode was
advanced is also ablated. This prevents tumor seeding and achieves complete hemostasis.10 Like
cryoablation, RFA does not leave a lasting impact on the breast’s silhouette, but the ablation
zone is palpable for several months.14
Real-time control and fine adjustment of treatment settings is pivotal to creating an
ablation volume of optimal shape and size.20 Most commonly, a super fine thermocouple-needle
system is inserted alongside the electrode into the tumor site. This form of thermometry is
considered invasive. These devices can only take single-point, often corrupt measurements, due
to their sensitivity to patient breathing, nearby vasculature, cardiac and bowel motion. 19,21 Noninvasive infrared thermometry can be used in addition to the thermocouple-needle system,
though it is far less accurate.19 The development of thermometry devices less susceptible to
artifacts during ablation is an area of copious investigation.20
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A challenge unique to hyperthermic ablation is the process of maintaining a homogenous
temperature zone. Heat dispersal is markedly influenced by proximity to major blood vessels;
therefore, multiple electrodes placed closely together are required to offset heat loss due to
perfusion. If a tumor is near the chest wall or axillary region, this convective cooling effect is
especially challenging, as significant vasculature runs in these regions.19 In such cases, the
ablation margin can become unpredictable.
Lastly, it must be noted that cell death due to heat is time dependent.12 The cell-dying
mechanism is the result of vascular thrombosis and gradual failure of the tumor’s
microcirculation. In the weeks following the procedure, progressive tissue ischemia results in an
expanding volume of cell death.3 Additionally, the immune system is activated by the processes
of necrosis and apoptosis, which aids in eradicating residual tumor cells over time.13 Due to these
delayed effects, it is postulated that complete ablation rates increase when the interval between
RFA and margin obtainment is prolonged.3 In studies where margins are harvested immediately
following RFA, cell death is likely underestimated. This is a major limitation seen in several
studies included for review.

Studies
A retrospective 2018 study reaffirms the importance of patient selection for RFA.17 Ito et
al. analyzed 386 patients across 10 institutions between 2003 and 2009; median patient age and
tumor diameter was 54 years and 1.6 cm, respectively.17 Notably, patients with tumor size of
larger than 2 cm in diameter were more likely to experience IBTR than patients with smaller
sized tumors (P<0.001). Following this trend, IBTR-free survival at 5 years was 97% if a
patient’s tumor was < 1cm, 94% between 1.1 to 2.0 cm, and 87% in instances of tumor size > 2
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cm. Lastly, recurrence following RFA was significantly higher in patients not treated with
radiation (18.2%) versus with those undergoing radiation (3.2%; P<0.001).17 In agreement with
the literature to date, Ito et al. establishes RFA as a highly successful procedure in treating
tumors < 2 cm in diameter, with the additional recommendation for concurrent radiation.17
A monumental 2018 study by Garcia-Tejedor et al. directly compared RFA with
immediate surgical excision to lumpectomy alone.10 Authors hypothesized RFA with excision
would reduce intraoperative margin involvement by 30%. Between 2013 and 2017, 40-patients
from a single institution were randomized 1:1 to the control (n=20) or study group (n=20);
median tumor size was 1.3 and 1.0 cm respectively, with each having an average participant age
of 64 years. These values and other baseline characteristics, including menopausal status, tumor
grade and molecular subtype, did not differ significantly amongst groups (P>0.05). Tumors were
primarily hormone positive, HER2 negative (35/40 total); only 1 patient allocated to the control
arm was triple negative (ER/PR negative and HER2 negative). Preoperative needle core biopsies
were compared to postoperative margins.10 Histological evaluation classified surgical margins
positivity in two separate ways: first, an intraoperative frozen section stained with Nicotinamide
adenine dinucleotide (NADH) diaphorase* turned blue in the presence of viable tumor cells;
second, if greater than 10% of the paraffin embedded specimen stained with Cytokeratin 18
(CK18) * turned orange.12 NADH causes an oxidation reaction in the cytoplasm of viable tumor
cells, producing a dark blue stain. This indicates tumor cells are still undergoing respiration
(alive), and the test is considered positive. Non-viable tumor cells stain pale gray, indicating they
are no longer respiring (dead), and the test is negative.11 CK18 and CK19 are found in the
cytoskeleton of epithelial tumors and are amongst the first proteins broken down in the cell death
process, turning the stain from orange to purple. Therefore, these intermediate filament keratins
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are markers for apoptosis of tumors. Staining is classified as the percentage of tumor cells with
positive staining: less than 10% (negative; purple color), 10%-25%, 26%-50%, 51%-75% and
76%-100% (positive; orange color).11 Clinical follow up took place 2-weeks after surgery and
then every 6-months for the next 2 years.10
At histologic evaluation, Garcia-Tejedor et al. observed absence of tumor viability in
80% of patients undergoing RFA plus excision, as opposed to only 45% with standard
lumpectomy.10 Authors detail frozen section results in only 16 of 20 patients in the RFA arm,
highlighting the challenge of this particular specimen acquisition. Prior to RFA, all tumors
showed NADH positivity, and afterwards, NADH positivity was lost in 13 of 16 tumors (81%),
which was considered significant (P<0.001). CK18 positivity was present in 19 of 20 cases
before RFA, and afterwards was considerably lower in all cases: 8-cases were negative, 11-cases
were less than 50% and 1-case showed positive staining (P<0.001). Notably, 100% of RFA
samples demonstrated a complete absence of staining with either NADH or CK18.10
Understandably, this detail is absent for the control arm, as staining protocol and interpretation
for lumpectomy specimens is standardized across institutions. Despite grouping, adjuvant
therapy was sufficient to treat patients with positive margins; no additional surgery was required.
At 25 months, no local or systemic recurrences were detected amongst all 40-patients.10 Though
on a moderate scale, the results demonstrated here by Garcia-Tejedor et al. provide baseline
evidence establishing RFA as equal or superior to lumpectomy in producing tumor-free
margins.10
The work published in 2016 by Knuttel et al. underlies the accepted rationalization of
margin status seen in Garcia-Tejedor et al. and other studies.18 Prior to its publication, the
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histopathological appearance of ablated tissue was understudied. Knuttel et al. retrospectively
assessed cell morphology and viability in 15 women with IDCA < 2.0cm in diameter. 18 The
histological material was acquired previously by independent studies in 2014.18 Patients of the
aforementioned studies underwent RFA followed by immediate mastectomy or local excision;
specimens were processed with standard H&E staining. Slides containing thermal lesions
showed distinct cellular distortion. This includes hyper-eosinophilic stroma and severely
elongated nuclei, especially around the probe insertion site. In their discussion, Knuttel et al.
refers to a trial that examined histopathological findings of tumors resected 91 days following
RFA.18 Specimens from the latter showed remarkably more degenerative changes than those in
Knuttel et al.18 Taken together, these studies further clarify the interpretation of tumor viability
through time, verifying the long-term effects of RFA.
A recent 2021 study further investigates how to reliably assess histological features postablation.12 Guma et al. correlates NADH staining of frozen sections to CK18 and CK19
immunostaining of paraffin-embedded tissue.12 Twenty women from a single institution
diagnosed with IDCA, underwent RFA with immediate surgical excision from 2013 to 2017;
average patient age and tumor size was 64 years and 1.1 cm, respectively. In agreement with
Knuttel et al., authors describe post-ablative degenerative changes with eosinophilic cytoplasm
and streaming nuclei, while the peripheral zone containing healthy tissue showed no change. 12,18
Frozen section staining revealed the following: 13 out of 16 patients (81%) were negative for
NADH; in 4 instances, frozen sections could not be obtained due to technical difficulties. Prior to
RFA, needle core biopsies were diffusely positive for CK18 and 19. Contrarily, post-RFA, 8patients were negative for CK18 and CK19, 5 showed less than 10% staining, 6 showed 10-25%
staining and one case was positive with 22.5% staining; 98% of tumors were CK18 and CK19
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negative or markedly reduced. A Cronbach alpha score of 0.8 indicates a strong correlation
amongst the various stains.12 This internal consistency is significant because when an
intraoperative section is not feasible, CK18 and CK19 can be used reliably in place of NADH. 12
Given this evidence, authors claim that by moving away from dependance on frozen sections,
surgery will not be required for tumor viability confirmation. Due to its simplicity and
reproducibility, immunostaining is highly generalizable, more reliable and cheaper than its
intraoperative counterpart.12

The data presented above establishes RFA as a promising alternative to breast conserving
surgery for patients diagnosed with IDCA measuring < 2 cm. As histological interpretation
standardizes, it is more likely RFA will transform to an in-office procedure. In the van de Voort
et al. 2021 meta-analysis, 89% (601/652) of tumors treated with RFA were completely ablated.
In comparison, only 80% (339/397) of patients undergoing cryoablation had a complete
response; these values varied significantly (P<0.001). Comprehensive analysis by van de Voort
further establishes RFA as having increased efficacy over cryoablation, with the added
reassurance that long term outcomes are not jeopardized.3

Part III: LA, MWA & HIFU
The following three mechanisms are newer to study in the field of breast cancer
treatment, and like RFA, utilize hyperthermia to ablate tumor cells. While each modality
employs a unique mechanism of heat production, the same processes of cellular necrosis and
delayed cell death described in RFA apply here. Additionally, it should be noted the major issues
encountered in RFA are also seen in studies of LA, MWA and HIFU. To reiterate, heat loss as a
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result of perfusion with major blood vessels leads to an uneven temperature distribution.19
Secondly, invasive thermometry is highly susceptible to artifact, however non-invasive
thermometry devices are less accurate than their counterparts.20 Cosmetically, LA, MWA and
HIFU produce excellent outcomes, and overall, little patient discomfort is reported. Below, each
technique is described in technical detail, followed by a review of the current literature.

A. LA
LA shares the most in common with RFA, however, it can be performed under local
anesthetic. Additionally, it is considered to be more accurate and safer near critical structures
than other modalities; hence, it is a mainstay of brain surgery.19 The laser fiber is guided by
ultrasound into the center of the tumor, consecutive illuminations are performed between 800
and 3600J (target temperature > 60℃), and then the treatment is completed with track-ablation.5
Procedure time is approximately 30-minutes and is considered grossly successful when the gas
formed during the ablation engulfs the tumor on ultrasound.5 Fluoroptic thermal probes are
inserted to monitor temperature by measuring how fast the emitted light decays.22,23 As with
RFA, charring is counteracted by a saline flow system situated alongside the laser fiber, and a
coolant spray is used to prevent skin burns.5

Studies
The Phase 2 Open-Label Trial performed in 2018 by Schwartzberg et al. is an industry
sponsored analysis of Novilase Laser Therapy system to treat IDCA.22 The chosen patient study
was extremely selective, excluding those with morbid obesity, renal insufficiency or
comorbidities impacting life expectancy. Additional exclusion criteria were anything preventing
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a patient from undergoing MRI, such as possessing a cardiac pacemaker or metallic implant.
Between 2012 to 2015, laser ablation was performed in 61-patients; four weeks later, subjects
underwent post-ablation MRI, followed by subsequent surgical excision; average age and tumor
diameter was 64 years and 1.1 cm, respectively. Tumors were primarily hormonal positive,
HER2 negative (50/61). Complete tumor ablation was observed in 84% of cases (51/61). Postablation MRI showed a negative predictive value of 92%, yet it failed to detect residual cancer in
64% of positive cases.22 Such a low rate of sensitivity weakens evidence for MRI to reliably
assess tumor viability. Authors claim imaging and pathology findings are strongly correlated;
however, their data suggests otherwise.22
In blatant contrast, Nori et al. is a retrospective 2018 study focusing on patients with
unresectable IDCA.5 Twelve elderly women with an average age and tumor size of 79 years and
1.2 cm, respectively, comprised the study population. MRI represents the most sensitive
technique to visualize a tumor, however baseline imaging was not feasible in most patients due
to severe comorbidities, including but not limited to: diabetes with end stage renal disease,
Parkinson’s and heart failure. Authors claim this represents a limitation of their study; yet,
alternatively, these restrictions actually enhance the merit of their conclusions, as they are typical
of this patient population. Complete ablation was grossly visualized on ultrasound for 100% of
patients, no serious complications of skin burn or infection occurred and all patients were
discharged the same day of treatment. Over 28 months, no patients demonstrated recurrence on
follow-up.5 In line with the fundamental purpose of minimally invasive ablative treatment, the
study population of Nori et al. is far more representative than Schwartzberg et al.5,22
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B. MWA
MWA is capable of ablating larger volumes of tumor and achieving higher intratumoral
temperatures than other modalities.2 Currently, microwaves are utilized in oncology to induce
full body hyperthermia. This process enhances the therapeutic effects of adjuvant radiation and
chemotherapy.19 MWA is also widely used to ablate thoracic and gastrointestinal tumors.19 Yet,
it remains the most understudied modality in the treatment of IDCA. Energy deposited by MWA
disrupts the dipole moment of water molecules, causing them to oscillate, which generates
friction and heat (target temperature > 54℃), leading to coagulative necrosis.24 Under the
guidance of ultrasound, the antenna is inserted percutaneously; placement is confirmed when
heat-generated echogenicity is detected; when the tumor site appears completely hyperechoic,
track-ablation mode is initiated and the procedure is completed.2 As compared to RFA, MWA
allows more energy to be deposited faster and reach lower depths; however, this increases the
risk of thermal injury and decreases predictability of the ablation zone.19

Study
A 2020 study retrospectively compared the efficacy of the standard nipple sparing
mastectomy (NSM) to microwave ablation alone to treat IDCA.2 Yu et al. analyzed 64-patient
cases taking place between 2014 and 2020 at one institution. Unlike studies discussed in
previous sections, the NSM (control) and MWA (study) group were grossly imbalanced, with 21
and 43 participants respectively. Additionally, the mean age of MWA patients was 24 years older
than those allocated for NSM (P<0.001). Other inconsistencies include menopausal status
(P<0.001) and the number of patients suffering comorbidities (P<0.001) in the MWA arm.
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However, tumor size was not significantly different with most measuring below 3 cm in diameter
(P=0.81).2
The clinical advantage of MWA for this particular patient population was evidenced by
the decreased operative time, post-operative hospitalization and blood loss, compared to NSM
(P<0.001).2 In agreement with previous studies, the ablation zone shrank rapidly over the first 6
months. Within the study arm, 2-patients experienced recurrence, aged 78 and 94, versus 3patients in the control; both MWA subjects denied additional treatment, however neither died
due to IDCA. Notably, most patients in this arm did not receive adjuvant therapy due to their
age, speaking to the effectiveness of MWA treatment over the average follow-up period of 26
months.2 Lastly, for all patients, the negative predictive value of MRI was 100%, which is
consistent with Schwartzberg et al. and other past studies.2,22 Several more studies are required to
support the data presented here.

C. HIFU
HIFU is unique in that it does not require a probe to be inserted through the skin and into
the tumor cavity. However, the procedure does require general anesthesia as it is extremely
sensitive to patient movement.25 Patients are positioned prone with their breasts immersed in
degassed water, and ultrasonic waves are sent by transducers in successive sweeps across the
tumor (target temperature > 50℃).19,25,26 In the setting of therapeutic ultrasound, the water acts
as an acoustic coupling agent, maximizing the contact between the ultrasound transducer and
insonated tissue; this generates focal acoustic energy, ablating the tumor.19,27 Procedure length
averages about 1 hour, however can extend up to 2-hours – the longest of all thermal ablative
techniques – as sufficient cooling time is needed between sonications.3 Echogenicity is again
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used to monitor the extent of treatment and determine its gross success, while tissue temperature
is monitored using non-invasive MR-thermometry.19,26 Complications and discomfort are
minimal, with breast edema being the most common adverse effect.26

Studies
Guan and Xu et al. were the first to directly compare HIFU to standard mastectomy. 26
This 2016 study, adopts the treat-and-resect protocol to characterize the impact of HIFU on
tumor vascular supply. Fifty patients were randomized 1:1 to HIFU with subsequent resection 12 weeks later (study group; n=25) or mastectomy alone (control group; n=25); patients and
providers were blinded to group allocation. Patients were diagnosed with IDCA with an average
age and tumor size of 48 years and < 5 cm in diameter, respectively; baseline characteristics and
tumor pathology did not differ amongst groups significantly (P>0.05).26
Compared to mastectomy margins, the vascular structure in the HIFU group was
thoroughly destroyed.26 Microthrombi were distributed throughout the capillaries, venules and
arterioles. Extensive damage was visualized in the tunica media and cellular margins were
blurred, demonstrative of coagulative necrosis. Pathologists also report signs of tumor
dissolution. Under electron microscopy, tumor integrity along with viable cell organelles were
visualized in the control group. Contrarily, the tumor capillary bed of the study group appeared
utterly disintegrated. At 1-year, local recurrence was detected in both groups, however this data
is not reported as the follow-up period is ongoing.26 Yet, these preliminary results prove HIFU
can irreversibly disrupt tumor angiogenesis, thereby halting its chaotic proliferation cycle of
growth.26
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In the same year, an industry sponsored study by Merckel et al. aimed to test a newly
developed HIFU system.25 Ten patients reflecting the prime candidate profile for thermal
ablation underwent the treat-and-resect protocol; participants were an average age of 54 years,
and diagnosed with a hormonally positive, HER2 negative tumor with a mean size of 2.0 cm.
Considering the purpose of this trial, several patients' treatments failed due to technical
difficulties. In 4 patients, the sonications sent from the device were misaligned and no tissue
coagulation occurred; however, in the remaining 6 patients, tumor necrosis was observed as in
Guan and Xu et al.25,26 As this study illustrates, HIFU is in its incipient form. Device
development, provider experience and randomized, prospective trials are required for any
conclusions to be made regarding this modality's efficacy.24

To conclude, LA, MWA and HIFU share the lowest volume of evidence in the treatment
of IDCA. Due to the novelty of these modalities, the studies demonstrate a large heterogeneity,
compared to cryoablation and RFA. Based on current literature, the most decisive data lies with
LA. Its shared treatment profile with that of RFA and successful application by Nori et al. in the
elderly, separates this technique’s potential from MWA and HIFU.5 Yet, in the 2021 metaanalysis by van de Voort, the primary reason for incomplete ablation in any of these three
modalities was device malfunction and technical difficulties, owing to the provider learning
phase.3 Both user experience and device development stand in the way of the clinical adoption of
LA, MWA and HIFU in the near future.
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Discussion
Three things need to be reliably proven for thermal ablation to supplant breast conserving
surgery as standard of care for IDCA. Depending on the population being treated, a nuanced
interpretation is required in regards to the following: First, the benefits of forgoing surgery must
outweigh the risks. Second, the ablation site and surrounding tissue must be confidently deemed
cancer free. Third, across a large population of patients, local recurrence must be very minimal,
or more preferably, absent. Here, the utility of thermal ablation in the setting of the elderly will
be reconciled.
It is without question that surgical excision is historically proven to lower the risk of local
cancer recurrence and metastasis, but at what cost? In considering a young or middle-aged
patient, choosing between lumpectomy versus a lesser proven procedure poses significantly more
debate than those near the end of life. For the geriatric patient, life expectancy prominently
impacts decision-making for both themselves, and their attending provider. In general, the
impaired ability to recover, fewer available financial resources, possible lack of transportation
and presence of comorbidities influence treatment choices. Through this lens, the information
presented here on thermal ablation can take on new, more tailored meaning.
As the above discussion already alluded to, thermal ablation procedures decrease
hospitalizations, postoperative infections and adverse events, and overall time of recovery for
this particular patient population. An example of this is demonstrated in Nori et al.5 Even in its
infancy, laser ablative technology is sufficiently sophisticated to allow same-day, out-patient
services. In terms of the elderly, this drastically reduces morbidity and mortality following
cancer treatment. Another clear advantage of thermal ablation is mentioned in Yu et al. where
blood loss and operative time is significantly improved over surgery.2 Although this is the only
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study to directly acknowledge this benefit, it can be assumed this is a general improvement
regardless of ablative modality.
Regarding the second parameter, deciphering the presence of residual cancer following
thermal ablation is a clear challenge of this field. Yet, major advances in terms of histology are
demonstrated by Garcia-Tejedor et al.10 Here, they prove a strong correlation amongst stains
performed on frozen and paraffin-embedded tissue. This consistency allows immunostaining to
be used as a surrogate marker for tumor viability, which is a more generalizable evaluation
method across institutions.10 Therefore, a needle core biopsy, rather than margins obtained in the
operating room, can be used to verify efficacy. This constitutes a major step towards moving
thermal ablation out of the hospitals and into the clinics.
A bigger challenge in this regard is the reliability of imaging. Cryoablation studies in
particular have not produced promising results in terms of imaging sensitivity. In Machida et al.,
the interobserver agreement was considerably low.15 To compound these findings, the sensitivity
of MRI to detect residual cancer in Poplack et al. and Simmons et al. was also unacceptably
low.9,16 Contrarily, the negative predictive value of MRI was consistently high amongst studies:
in Schwartzberg et al. it was 92% and Yu et al. showed a 100% success rate. 2,22 However, as
Nori et al. recognizes, MRI is not always possible in the geriatric population.5 For these patients,
pacemakers, renal insufficiency and other factors contraindicate them from undergoing MRI.5 In
this case, the third aspect of local recurrence control becomes the single most important factor.
The ICE3 trial has one of the longest follow-up periods discussed in the present review.8
At the 3-year interim, 98% of patients (191/194) were negative for IBTR. As mentioned before,
significant bias went into patient selection.8 However, in terms of legitimate clinical practice, the
results of ICE3 portray a likely prognosis for patients who are deemed candidates for thermal
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ablation.8 What is more intriguing, will be the final results published in 2023 at the completion of
its 5-year study period. Ito et al. is another high-powered study which demonstrated strong
longitudinal value of thermal ablation.17 Here, in patients with tumor size less than 1 cm, IBTRfree survival at 5 years was 97% and 94% up to 2.0 cm.17 Lastly, Nori et al. corroborated these
results by publishing that at 28 months, 0% of their study population (12/12) showed local
recurrence.5 It cannot be overlooked how when applied to a patient in their seventh decade, an
additional 2 to 5-years of tumor free survival is significantly more valuable than a patient in their
thirties. Using this perspective, the efficacy of thermal ablation escalates.
Throughout this review, the time-dependent effects of hyperthermic ablation have been
discussed, and in terms of IBTR, its most pertinent manifestation occurs in the 2016 study by
Garcia-Tejedor et al.10 At histologic evaluation, neither the control or study group demonstrated
100% tumor-free margins. However, regardless of positive margin status, authors go on to say no
patients required additional procedures. At 25 months, no local or systemic recurrences occurred
for any participant.10 In the control group, this is directly related to adjuvant therapy. However,
in the RFA with subsequent excision group, it may be attributed to one of two factors: either
adjuvant therapy, or, late-onset cell death secondary to thermal ablation and immune system
activation.3,10 Most likely, both processes are at work on residual tumor cells. The 2021 metaanalysis by van de Voort et al. noted the thermal ablative studies in which margin resection was
delayed showed higher complete ablation rates.3 Eight studies extracted margins in under 14days following ablative therapy, and demonstrated an overall complete ablation rate of 67%.3 In
stark contrast, 10-studies which delayed extraction beyond 2-weeks, showed an overall complete
ablation rate of 86%. Authors conclude, these results are likely due to delayed onset of cell
death.3
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In theory, given enough time, the late-onset effects of thermal ablation may
independently resolve residual cancer – yet this is not standard of care. Adjuvant therapy,
regardless of age, is almost always recommended. Therefore, future studies looking at thermal
ablation, without subsequent resection, over a long period of time would be beneficial in building
evidence for its clinical adoption. Two studies of this nature are currently underway in Japan and
the Netherlands. The RAFAELO study is a prospective phase III study taking place across 11
institutions where patients will undergo RFA without surgical excision.28 Follow-up is planned
for 5-years and results will be compared to previous randomized control studies of lumpectomy
or partial mastectomy.28 More interestingly, the THERMAC trial plans to randomize 63 patients
1:1:1 into three treatment arms: cryoablation, RFA and MWA.29 They intend to prolong the
interval between thermal ablation and surgical excision to allow adequate assessment of
complete ablation on MRI and pathology. Therefore, authors assert their results will take into
account both direct and delayed effects of thermal ablation.29 In terms of the geriatric population,
long-term positive results from these trials should provide sufficient evidence to assure tumor
free survival, likely until the end of these patients' lives.
Taken together, the three conditions presented in the introductory paragraph of this
discussion have been fulfilled. Amongst the elderly, for several reasons discussed at length, the
minimally invasive option reigns superior to that of general anesthesia and hospitalization.
Although the determination of cancer-free margins is not absolute, more exposure to thermal
ablation across institutions will improve imaging interpretation, and the detection of residual or
recurrent cancer; alternatively in place of surgical margins, the more widely reproducible,
economical process of immunostaining can be used to determine tumor viability of needle core
biopsies. Lastly, the longevity of thermal ablation to control local recurrence is gaining
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considerable evidence. As discussed here, several studies demonstrate an IBTR of 2 to 5 years.
This proposed time frame transcends expectations for those near end of life, and provides
significant opportunity for safe treatment without loss of efficacy.

Conclusion
The purpose of this analysis was to determine the efficacy of thermal ablation as a
reasonable alternative to surgical excision in the treatment of IDCA. This research is not only
important, but vital to meeting the ever-increasing demand of an aging population and substantial
healthcare worker shortages. Habrawi et al. reports that nearly 70% of those diagnosed with
breast cancer each year are classified as low-risk and early stage.4 This sizable population
represents an opportunity to build upon the growing volume of preliminary data for thermal
ablation.30
While several modalities of thermal ablation exist, the most promising are cryoablation
and RFA. These techniques show the highest rate of complete tumor ablation and are the most
effective in controlling long term local recurrence. A limitation amongst this field of study is the
lack of high powered, prospective trials. However, the completion of the ICE3, RAFAELO and
THERMAC trials will help fill this void.28,29 Until this data is published, breast conserving
surgery will endure as the standard of care for the majority of patients. Yet, in the special
consideration of the elderly, the use of thermal ablation is justifiable in those unsuitable for
surgery or wish to pursue a more minimally invasive option. Further research in this field is
strongly warranted, as the reduced morbidity, psychosocial and economic impact of these
modalities for the geriatric population is undeniable.
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Appendix
Acronyms: cytokeratin 18 (CK18), ductal carcinoma in situ (DCIS), extensive intraductal
component (EIC), high intensity focused ultrasound (HIFU), invasive ductal carcinoma
(IDCA), laser ablation (LA), magnetic resonance imaging (MRI), microwave ablation (MWA),
nicotinamide adenine dinucleotide (NADH)radiofrequency ablation (RFA)

A: Matrix of included studies

REFERENCE & PURPOSE

SOURCES

DATA

VARIABLES

Article Title
Primary
Author

Year
Published

Ablation
Modality
& Purpose

Study
Size
(n)

Inclusion/
Exclusion
Criteria

Sample
Design

Year
Data
Collected

Control

Intervention

A Pilot Study of
Ultrasound-Guided
Cryoablation of Invasive
Ductal Carcinomas up to
15mm with MRI FollowUp and Subsequent
Surgical Resection

2015

Cryoablation

20

IDCA or DCIS
Unifocal
Tumor
size <15mm
EIC < 25%

Prospective
Single arm

Not reported

Not
applicable

Cryoablation followed
by surgical excision 4-6
weeks later

Evaluate
cryoablation efficacy
and predictive value
of MRI in detecting
residual tumor or
recurrence

CONCLUSION

Authors conclude RFA is effective at
local tumor control in patients with
tumor size below 2 cm.

2 institutions
MRI shows poor correlation with
histology following cryoablation.

Metastasis

Poplack et al.
Single-Centre
Experience with
Percutaneous
Cryoablation of Breast
Cancer in 23
Consecutive Nonsurgical Patients

2015

Cryoablation

23

Evaluation of
efficacy in nonoperable patients;
focus on elderly
population

Ineligible or
denied surgery
Unifocal
Negative
metastasis

Prospective
Single arm

01/2013 01/2015

Not
applicable

Cryoablation

Cryoablation is an effective means to
local tumor control. Authors discuss
procedural steps in detail.

Not reported

Not
applicable

(1) RFA followed by
immediate surgical
excision

Cell morphology is uniquely impacted
by each technique. Assessment of
treatment effect is likely impacted by
delayed effects of heat on tumor cells,
which possibly underestimates
effectiveness of thermal therapies.

1 institution

Metastasis

Cazzato et al.
Histopathology of Breast
Cancer After MRIGuided High-Intensity
Focused Ultrasound and
RFA

2016

RFA
HIFU

25

Evaluate margin
status following
treatment with RFA
or HIFU, followed
by surgical excision

Knuttel et al.

IDCA
Tumor size 1 2.0 cm

Prospective
staining
Historic
specimen
acquisition

Not reported

(2) HIFU followed by
surgical excision 4-6
days later

Two arms
1 institution

A Phase II Trial
Exploring the Success of
Cryoablation Therapy in
the Treatment of
Invasive Breast
Carcinoma. Results from
ACOSOG (Alliance)
Z1072

2016

Cryoablation

86

Evaluation of
complete tumor
ablation rate and
predictive value of
MRI

IDCA or DCIS
Unifocal
Tumor size <
2cm
EIC < 25%

Prospective
Single arm

03/2009 06/2013

Not
applicable

Cryoablation followed
by MRI within 14-28
days and surgical
excision within 28 days

Cryoablation effectively treated 92%
of unifocal tumors. Several tumors
were determined to be multifocal at
follow-up MRI. Post-ablation MRI
showed a negative predictive value of
81%.

09/2012 06/2014

Not
applicable

HIFU followed by
surgical excision 48h to
10 days later

Multiple factors were identified as
having a negative impact on HIFU
efficacy, including breathing patterns
and location of tumor in relation to the
chest wall and vasculature.

02/2014 08/2014

Radical
mastectomy

HIFU followed by
modified radical
mastectomy 1-2 weeks
later

Thermal ablation showed considerable
impact on tumor vasculature while
leaving healthy breast tissue intact.

06/2012 05/2015

Not
applicable

Laser ablation followed
by surgical excision
within 28 days

Histology confirmed loss of postablation cell viability. Authors
comment on technical aspects of the
procedure/

19
institutions

Lobular
carcinoma

Simmons et al.
First Clinical Experience
with a Dedicated MRIGuided High-Intensity
Focused Ultrasound

2016

10

IDCA
Tumor size >
1cm

Determining the
safety profile of a
new transducer
(industry sponsored)

Merckel et al.
Damage Effect of HighIntensity Focused
Ultrasound on Breast
Cancer Tissues and their
Vascularities

HIFU

2016

HIFU

Prospective
Single arm
1 institution

50

Evaluation of HIFU
on tumor vasculature

IDCA
Tumor size <
5cm
Unifocal

Prospective
Two arms
1 institution

Guan & Xu et al.
Phase II Open-Label
Trial Investigating
Percutaneous Laser
Ablation for Treatment
of Early-Stage Breast
Cancer: MRI, Pathology,
and Outcome
Correlations
Schwartzberg et al.

2018

LA
Evaluation of the
efficacy and safety
profile of a new
transducer (industry
sponsored)

61

IDCA or DCIS
Tumor size <
20mm
Multifocal

Prospective
Single arm
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(n)
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Design

Year
Data
Collected

Control

Intervention

Radiofrequency
Ablation of Breast
Cancer: A
Retrospective Study

2018

RFA

386

Tumor size < 3.5cm

Retrospective
Single arm

07/2003 06/2009

Not
applicable

RFA

RFA should not be offered to patients
without also performing radiation
therapy. Local recurrence rate
without irradiation versus those with
irradiation (p<0.001).

09/2013 02/2017

Lumpectomy

RFA followed by
immediate surgical
excision

RFA reduced margin involvement
more consistently than traditional
lumpectomy (p=0.022).

10/2006 10/2014

Not
applicable

Cryoablation

Suspicious enhancement on 1st MRI
status post cryoablation was resolved
on 2nd MRI following an additional
cryoablation treatment and adjuvant
therapy. It is unclear if identified sites
were resolved due to cryoablation or
adjuvant therapy.

10/2014 05/2020

Nipple
sparing
mastectomy

MWA

MWA is as effective as surgical
intervention in preventing tumor
progression. The MWA study group
had significantly more elderly
patients with comorbidities compared
to the control group.

01/2017 02/2020

Not
applicable

Cryoablation

Cryoablation was effective in
preventing recurrent disease
throughout the 2-year follow-up
period. Small sample size of this
study makes proving non-inferiority
of cryoablation to surgery hard to
prove.

09/2013 02/2017

Not
applicable

RFA with immediate
surgical resection

CK18 is as effective as NADH in
detecting residual tumor viability
following RFA. CK18 and CK19
immunohistochemistry is simpler and
more economical than methods using
frozen tissues.

10/2014 - End
date not
reported

Not
applicable

Cryoablation

The ProSense Cryosurgical System is
effective in preventing ipsilateral
breast tumor recurrence at 3-year
follow-up. Trial follow-up period to
continue until 2024 for a total of 5
years.

Studies ranging
2003 - 2018

Not
applicable

Not applicable

Review focused on patients with
breast cancer tumors <2cm in
diameter. Higher complete ablation
rates were found in studies
performing delayed resection than in
studies performing immediate
resection. Complete ablation rates
were highest with RFA (92%), MWA
(87%) and cryoablation (85%).

Evaluation of RFA
as stand-alone
therapy or in
concert with
radiation

Ito et al.

Radiofrequency
Ablation Followed by
Surgical excision
Versus Lumpectomy
for Early-Stage Breast
Cancer: A
Randomized Phase II
Clinical Trial

2018

RFA

Multifocal
10
institutions

40

Evaluation of RFA
with surgical
excision versus
lumpectomy alone

IDCA
Tumor size < 20cm
< 20% EIC
Her2 negative

Prospective
Two arms
1 institution

Neoadjuvant therapy
Lobular carcinoma

García-Tejedor et al.
MRI Findings After
Cryoablation of
Primary Breast
Cancer Without
Surgical Excision

2019

Cryoablation

54

IDCA or DCIS
Tumor size < 15mm
Her2 negative

Evaluate predictive
value of MRI in
detecting residual
tumor or recurrence

Retrospective
Single arm
Not reported

Machida et al.
Microwave Ablation
Versus Nipple
Sparing Mastectomy
for Breast Cancer <5
cm: A Pilot Study

2020

64

Evaluation of local
and systemic tumor
recurrence in
patients treated
with MWA therapy
alone or
lumpectomy

Yu et al.

Cryoablation: A
Promising NonOperative Therapy for
Low-Risk Breast
Cancer

MWA

2021

Cryoablation

12

Evaluation of
therapeutic efficacy
without surgical
excision

IDCA
Tumor size < 5cm

Retrospective
Two arms

Multifocal
Extensive EIC

1 institution

IDCA
Tumor size < 1.5mm
HER2 negative
Unifocal

Prospective
Single arm
1 institution

Habrawi et al.
Assessment of Tumor
Cell Death After
Percutaneous
Ultrasound-Guided
Radiofrequency
Ablation of Breast
Carcinoma: A
Prospective Study

2021

RFA

20

Evaluate predictive
value of different
staining techniques
in assessing
margins for tumor
cell viability

IDCA
Tumor size < 20mm
Unifocal

Prospective
Single arm
1 institution

Neoadjuvant therapy
EIC >20%

Guma et al.
Cryoablation Without
Excision for LowRisk Early-Stage
Breast Cancer: 3-Year
Interim Analysis of
Ipsilateral Breast
Tumor Recurrence in
the ICE3 Trial

2021

Cryoablation

194

Evaluation of the
efficacy of a new
transducer
(industry
sponsored)

IDCA
Tumor size < 2cm
HER2 negative
EIC < 25%

Prospective
Single arm
Multi-center

Multifocal

Fine et al.
Thermal Ablation as
an Alternative for
Surgical Resection of
Small (< 2cm) Breast
Cancers
Van de Voort et al.

2021

Cryoablation, RFA,
MWA, HIFU and
LA
Evaluation of
complete ablation
rate

Not
applicable

Tumor size < 2cm

Meta-analysis

Exclusion if failure
to report complete
ablation of tumor,
ablation performed
after surgical
excision and review
literature

Multi-center
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Multicenter Study to
Standardize and
Evaluate the Efficacy of
Radiofrequency
Ablation Therapy for
Early Breast Cancer
(RAFAELO Study)

Ongoing

RFA

372

Ductal
carcinoma
Tumor size <
1.5cm
Unifocal

Prospective
Two arms

08/2013 11/2017

Lumpectomy
or Partial
Mastectomy

RFA

IDCA
Tumor size <
2cm
Unifocal

Prospective
Three arms

Evaluation of
complete ablation
rate without surgical
excision

Patients randomized to study
or control groups.

9
institutions

CONCLUSION

This phase III study intends to
demonstrate the non-inferiority
of RFA to standard breast
conserving treatment in terms of
ipsilateral breast tumor
recurrence.

Kinoshita et al.
Treatment of EarlyStage Breast Cancer
with Percutaneous
Thermal Ablation, an
Open-Label
Randomized Phase II
Screening Trial:
Rationale and Design of
the THERMAC Trial
Van de Voort et al.

Ongoing

Cryoablation, RFA
and MWA
Evaluation of
complete ablation
rate using CK8/18
and H&E staining.
Secondary outcome
to evaluate
predictive value of
MRI.

63

Date of first
enrollment:
04/2021

Multi-center
Neoadjuvant
therapy
EIC > 25%

Recruitment
Status:
Recruiting

Not
applicable

Patients randomized 1:1:1 to
one of three thermal ablative
techniques. Three months
later, surgical excision will
be performed to determine
efficacy. Patients and
physicians will not be
blinded.

The technique demonstrating the
highest tumor ablation rate will
be chosen to be studied in a
phase III trial comparing it to
standard of care (breast
conserving surgery).

